- Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
-
Mak LY, Seto WK, Yuen MF
- KMID: 2538223
- Clin Mol Hepatol.
- 2023 Jan;29(1):191-193.
- doi: 10.3350/cmh.2022.0410
-
- CITED
-
- Close
- SHARE
-
- Close
- Steatotic liver disease: Know your enemies
-
Mak LY
- KMID: 2554423
- Clin Mol Hepatol.
- 2024 Apr;30(2):171-173.
- doi: 10.3350/cmh.2024.0078
-
- CITED
-
- Close
- SHARE
-
- Close
- Screening strategy for non-alcoholic fatty liver disease
-
Zhang S, Mak LY, Yuen MF, Seto WK
- KMID: 2539794
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S103-S122.
- doi: 10.3350/cmh.2022.0336
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of different viral biomarkers on the management of chronic hepatitis B
-
Mak LY, Hui RWH, Fung J, Seto WK, Yuen MF
- KMID: 2541405
- Clin Mol Hepatol.
- 2023 Apr;29(2):263-276.
- doi: 10.3350/cmh.2022.0448
Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess... -
- CITED
-
- Close
- SHARE
-
- Close
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
-
Hui RWH, Mak LY, Seto WK, Yuen MF
- KMID: 2531368
- Clin Mol Hepatol.
- 2022 Jul;28(3):408-424.
- doi: 10.3350/cmh.2022.0012
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved... -
- CITED
-
- Close
- SHARE
-
- Close
- New Biomarkers of Chronic Hepatitis B
-
Mak LY, Seto WK, Fung J, Yuen MF
- KMID: 2464306
- Gut Liver.
- 2019 Nov;13(6):589-595.
- doi: 10.5009/gnl18425
Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective
-
Hui RWH, Mak LY, Cheung TT, Lee VHF, Seto WK, Yuen MF
- KMID: 2541401
- Clin Mol Hepatol.
- 2023 Apr;29(2):217-229.
- doi: 10.3350/cmh.2022.0399
Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
-
Hui KY, Fung J, Cheung KS, Mak LY, Seto WK, Yuen MF
- KMID: 2540416
- Gut Liver.
- 2023 Mar;17(2):280-287.
- doi: 10.5009/gnl220122
Background/Aims: Hepatitis B surface antigen (HBsAg) seroclearance remains uncommon in chronic hepatitis B (CHB) infection. During acute flares of CHB (AFOCHB), alanine aminotransferase elevation reflects a mounting immune response toward... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
-
Mak LY, Ko KL, To WP, Wong DKH, Seto WK, Fung J, Yuen MF
- KMID: 2506442
- Gut Liver.
- 2020 Sep;14(5):665-668.
- doi: 10.5009/gnl19434
Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
-
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF
- KMID: 2538211
- Clin Mol Hepatol.
- 2023 Jan;29(1):146-162.
- doi: 10.3350/cmh.2022.0172
Background/Aims: We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of... -
- CITED
-
- Close
- SHARE
-
- Close
